A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors (FLAGSHP-1)
Advanced or Metastatic Solid Tumors

About this trial
This is an interventional treatment trial for Advanced or Metastatic Solid Tumors focused on measuring SHP2, PTPN11, solid tumor, advanced solid tumor, metastatic solid tumor, neoplasms, solid malignancies, targeted therapy, colorectal cancer, CRC, head and neck squamous cell carcinoma, HPV Negative HNSCC, molecular alterations, cetuximab, Erbitux, Chordoma
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- Willing and able to give written informed consent
- Have histologically or cytologically confirmed advanced or metastatic solid tumor
- There is no available standard systemic therapy available for the patient's tumor histology and/or molecular biomarker profile; or standard therapy is intolerable, not effective, or not accessible; or patient has refused standard therapy
- Able to swallow oral medication
- Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- Adequate cardiovascular, hematological, liver, and renal function
- Willing to comply with all protocol-required visits, assessments, and procedures
Exclusion Criteria:
- Previous treatment with a SHP2 inhibitor
- Documented PTPN11 mutations
- Is currently receiving another study therapy or has participated in a study of an investigational agent and received study therapy within 4 weeks of the first dose of ERAS-601
- Received prior palliative radiation within 7 days of Cycle 1, Day 1
- Have primary central nervous system (CNS) disease or known active CNS metastases and/or carcinomatous meningitis
- Prior surgery (e.g., gastric bypass surgery, gastrectomy) or gastrointestinal dysfunction (e.g., Crohn's disease, ulcerative colitis, short gut syndrome) that may affect drug absorption
- Active, clinically significant interstitial lung disease or pneumonitis
- History of thromboembolic or cerebrovascular events ≤ 12 weeks prior to the first dose of study treatment
- History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO
- Have any underlying medical condition, psychiatric condition, or social situation that, in the opinion of the Investigator, would compromise study administration as per protocol or compromise the assessment of AEs
- Are pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the trial
Sites / Locations
- University of Alabama at BirminghamRecruiting
- University of California, San DiegoRecruiting
- Sarah Cannon Research Institute (Florida Cancer Specialists)Recruiting
- Massachusetts General HospitalRecruiting
- Washington UniversityRecruiting
- Comprehensive Cancer Centers of NevadaRecruiting
- Memorial Sloan Kettering Cancer CenterRecruiting
- University of North CarolinaRecruiting
- University of CincinnatiRecruiting
- University of PennsylvaniaRecruiting
- Sarah Cannon Research Institute (Tennessee Oncology)Recruiting
- Mary Crowley Cancer ResearchRecruiting
- The University of Texas MD Anderson Cancer CenterRecruiting
- Peter MacCallum Cancer CentreRecruiting
- Linear Clinical ResearchRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Experimental
Dose Escalation (Part A): ERAS-601 monotherapy
Dose Escalation (Part B): ERAS-601 monotherapy
Dose Escalation (Part C): ERAS-601 monotherapy
Dose Escalation and Dose Expansion (Part D): ERAS-601 in combination with cetuximab
Dose Escalation and Dose Expansion (Part E): ERAS-601 in combination with pembrolizumab
ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
ERAS-601 monotherapy will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression, or withdrawal of consent.
ERAS-601 will be administered in sequential ascending doses to study participants with advanced or metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent.
ERAS-601 will be administered in sequential ascending doses with cetuximab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or colorectal cancer (CRC).
ERAS-601 will be administered in sequential ascending doses with pembrolizumab to study participants with advanced metastatic solid tumors until unacceptable toxicity, disease progression or withdrawal of consent. Once the combination therapy recommended dose has been determined, this will be administered to study participants with HPV negative advanced or metastatic head and neck squamous cell carcinoma (HNSCC) or non small cell lung cancer (NSCLC).